PDF herunterladen
Thromb Haemost 2004; 92(04): 791-796
DOI: 10.1160/TH03-10-0618
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy

A pharmacokinetic study
Lucy A. Norris
1   Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland
2   Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK
,
John Bonnar
1   Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland
2   Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK
,
Mark P. Smith
1   Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland
2   Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK
,
Philip J. Steer
1   Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland
2   Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK
,
Geoff Savidge
1   Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James’s Hospital and Coombe Women’s Hospital, Dublin, Ireland
2   Chelsea and Westminster Hospital and The Haemophilia Reference Centre, St. Thomas Hospital, London, UK
› InstitutsangabenFinancial support: Tinzaparin was supplied by Leo Pharma free of charge and the cost of the anti-Xa analysis was also funded.
Weitere Informationen

Publikationsverlauf

Received 06. Oktober 2003

Accepted after resubmission 08. August 2004

Publikationsdatum:
06. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

Low molecular weight heparin (LMWH) is used increasingly for prophylaxis and treatment of venous thromboembolism during pregnancy. However, the prophylactic dose for patients at moderate risk varies between centers, and the recommended LMWH dose for the non pregnant patient is frequently used in pregnant women. The aim of this study was to investigate the effects of pregnancy on the pharmacokinetics of anti-Xa levels during moderate risk thromboprophylaxis with the LMWH, tinzaparin. In 24 pregnant women, one of three doses of tinzaparin (50, 75 or 100 IU/kg) were given according to the treating physician’s assessment of their risk profile. Four-hour peak anti-Xa levels were measured throughout pregnancy and 24-hour profiles were measured at 28 and 36 weeks gestation. Doses were adjusted when peak anti-Xa levels fell below 0.1 IU/ml and, in some cases, when levels at 10 and 18 hours post injection were undetectable (<0.05 IU/ml). Our results showed that women receiving tinzaparin (50 IU/kg) frequently had peak (4 hour) anti-Xa levels below 0.1IU/ml and that 46% of these patients required dose adjustment. Similarly anti-Xa levels were also found to be low over the 24-hour period. A starting dose of 75 IU/kg, once daily, gave greater anti-Xa cover over the 24-hour period and may avoid the need for dose adjustment. The results suggest that the pharmacokinetics of tinzaparin are affected by pregnancy. Larger studies are required to determine whether an increased tinzaparin dose (75 IU/kg) would be more effective in the prevention of thrombosis during pregnancy than 50 IU/kg

Keywords

Clinical trials - heparins / LMWH - deep vein thrombosis - familial thrombosis
 

  • References

  • 1 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.
    CrossrefPubMedSuche in Google Scholar
  • 2 Bonnar J. Venous thromboembolism and pulmonary embolism. In: Turnbull’s Obstetrics. Third edition. Chamberlain G, Steer PJ. Eds. Churchill Livingstone; London: 2001: 671-80.
    Suche in Google Scholar
  • 3 Pabinger I, Grafenhofer H, Kyrle PA. et al. Temporary increase in the risk of recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100 (03) 1060-2.
    CrossrefPubMedSuche in Google Scholar
  • 4 Hull RD, Raskob GE, Brant RF. et al. Low molecular weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000; 160: 229-36.
    CrossrefPubMedSuche in Google Scholar
  • 5 Sanson BJ, Lensing AWA, Prins MH. et al. Safety of low-molecular-weight heparin in pregnancy – a systematic review. Thromb Haemost 1999; 81: 668-72.
    Thieme ConnectPubMedSuche in Google Scholar
  • 6 Lepercq J, Conard J, Borel-Derlon A. et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynecol 2001; 108: 1134-40.
    PubMedSuche in Google Scholar
  • 7 Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism during pregnancy. Br J Obstet Gynecol 2000; 107: 1116-21.
    CrossrefPubMedSuche in Google Scholar
  • 8 Brenner B, Hoffman R, Blumenfeld Z. et al. Gestational outcome in thrombophilic women treated for recurrent pregnancy loss. Thromb Haemost 2000; 83 (05) 693-7.
    Thieme ConnectPubMedSuche in Google Scholar
  • 9 Dulitzki M, Pauzner R, Langevitz P. et al. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87: 380-3.
    CrossrefPubMedSuche in Google Scholar
  • 10 Samama MM, Poller L. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 1995; 15 (01) 119-23.
    PubMedSuche in Google Scholar
  • 11 Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002; 100: 3470-8.
    CrossrefPubMedSuche in Google Scholar
  • 12 Liezorovicz A, Picolet H, Peyrieux JC. et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 1991; 78: 412-16.
    CrossrefPubMedSuche in Google Scholar
  • 13 Planes A, Samama MM, Lensing AWA. et al. Prevention of deep vein thrombosis after hip replacement. Comparison between two low molecular weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81: 22-25.
    Thieme ConnectPubMedSuche in Google Scholar
  • 14 Hull R, Raskob G, Pineo G. et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6.
    CrossrefPubMedSuche in Google Scholar
  • 15 Smith MP, Norris LA, Steer PJ. et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190 (02) 495-501.
    CrossrefPubMedSuche in Google Scholar
  • 16 Fossler MJ, Barret JS, Hainer JW. et al. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. Am J Health Syst Pharm 2001; 58 (17) 1614-21.
    PubMedSuche in Google Scholar
  • 17 Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337: 688-98.
    CrossrefPubMedSuche in Google Scholar
  • 18 Eldor A. The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 104: 3-13.
    CrossrefPubMedSuche in Google Scholar
  • 19 Pauzner R, Dulitski M, Langevitz P. et al. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost 2001; 86: 1379-84.
    Thieme ConnectPubMedSuche in Google Scholar
  • 20 Sephton V, Farquharson RG, Topping J. et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101 (06) 1307-11.
    PubMedSuche in Google Scholar
  • 21 Dahlman TC, Hellgren MSE, Blomback M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. Am J Obstet Gynecol 1989; 161: 420-5.
    CrossrefPubMedSuche in Google Scholar
  • 22 Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335 (02) 108-14.
    CrossrefPubMedSuche in Google Scholar
  • 23 Casele HL, Laifer SA, Woelkers DA. et al. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 05: 1113-7.
    PubMedSuche in Google Scholar
  • 24 Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. Br J Obstet Gynecol 2003; 110: 139-44.
    CrossrefPubMedSuche in Google Scholar
  • 25 Bonnar J, Green R, Norris L. Inherited thrombophilia and pregnancy: the obstetric perspective. Semin Thromb Haemost 1998; 24: 49-53.
    PubMedSuche in Google Scholar
  • 26 Blombäck M, Bremme K, Hellgren M. et al. Thromboprophylaxis with low molecular mass heparin, “Fragmin” (dalteparin) during pregnancy – a longitudinal safety study. Blood Coagul Fibrinolysis 1998; 09: 1-9.
    PubMedSuche in Google Scholar
  • 27 Ellison J, Thomson AJ, Conkie JA. et al. Thromboprophylaxis during caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins- dalteparin, enoxaparin and tinzaparin. Thromb Haemost 2001; 86: 1374-8.
    Thieme ConnectPubMedSuche in Google Scholar